Covington, Skadden Rep Merck's $1.9B Pandion Buy
Merck & Co. said Thursday it's buying clinical-stage autoimmune and inflammatory disease biotechnology group Pandion Therapeutics Inc. in a $1.85 billion deal guided by Covington & Burling and Skadden....To view the full article, register now.
Already a subscriber? Click here to view full article